Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.
暂无分享,去创建一个
Erich A. Peterson | Caleb K. Stein | O. Stephens | B. Barlogie | G. Morgan | E. Tian | M. Zangari | B. Walker | F. Davies | J. Epstein | F. van Rhee | C. Stein | N. Weinhold | S. Chavan | C. Ashby | T. Meissner | L. Rasche | C. Heuck | N. Weinhold | C. Ashby | L. Rasche | S. S. Chavan | C. Stein | O. W. Stephens | R. Tytarenko | M. A. Bauer | T. Meissner | S. Deshpande | P. H. Patel | T. Buzder | G. Molnar | E. A. Peterson | F. van Rhee | M. Zangari | S. Thanendrarajan | C. Schinke | E. Tian | J. Epstein | B. Barlogie | F. E. Davies | C. J. Heuck | B. A. Walker | G. J. Morgan | S. Thanendrarajan | C. Schinke | R. Tytarenko | P. Patel | M. Bauer | T. Buzder | G. Molnar | S. Deshpande | B. Walker | Shayu Deshpande | Purvi Patel
[1] Shankar Vembu,et al. PhyloWGS: Reconstructing subclonal composition and evolution from whole-genome sequencing of tumors , 2015, Genome Biology.
[2] Yongsheng Huang,et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.
[3] Gábor E. Tusnády,et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics , 2016, Genome Biology.
[4] B. Barlogie,et al. The Clinical Value of Molecular Subtyping Multiple Myeloma Using Gene Expression Profiling , 2015, Leukemia.
[5] Julian Gehring,et al. SomaticSignatures: inferring mutational signatures from single-nucleotide variants , 2014, bioRxiv.
[6] C. Bastard,et al. Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.
[7] D. Hose,et al. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma , 2016, Haematologica.
[8] K. Stamatopoulos,et al. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. , 2016, Blood.
[9] Hong Chang,et al. Analysis of PTEN deletions and mutations in multiple myeloma. , 2006, Leukemia research.
[10] T. Chevassut,et al. The Genetic Architecture of Multiple Myeloma , 2014, Advances in hematology.
[11] G. Morgan,et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients , 2014, Blood Cancer Journal.
[12] B. Barlogie,et al. Curing myeloma at last: defining criteria and providing the evidence. , 2014, Blood.
[13] G. Parmigiani,et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.
[14] Philip M Kluin,et al. Double-hit B-cell lymphomas. , 2011, Blood.
[15] Xiaoyu Chen,et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications , 2016, Bioinform..
[16] A. McKenna,et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.
[17] John Crowley,et al. The molecular classification of multiple myeloma. , 2006, Blood.
[18] L. Bullinger,et al. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M3P) , 2015, Annals of Hematology.
[19] S. Carr,et al. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.
[20] Stein Aerts,et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia , 2012, Nature Genetics.
[21] J. Carpten,et al. Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.
[22] Winnie S. Liang,et al. Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease , 2013, British journal of haematology.
[23] Lisa J. Murray,et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms , 2013, Leukemia.
[24] Trevor J Pugh,et al. Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.
[25] L. Bullinger,et al. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in ‐17p high risk disease , 2015, British journal of haematology.
[26] Gordon Cook,et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] N. Schultz,et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms , 2016, Nature.
[28] Gordon Cook,et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma , 2014, Nature Communications.
[29] C. Curtis,et al. A Big Bang model of human colorectal tumor growth , 2015, Nature Genetics.
[30] Benjamin J. Raphael,et al. Pan-Cancer Network Analysis Identifies Combinations of Rare Somatic Mutations across Pathways and Protein Complexes , 2014, Nature Genetics.
[31] A. Look,et al. Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. , 2012, Blood.
[32] M. Weitzman,et al. APOBEC3 proteins and genomic stability , 2012, Cell cycle.